Company Overview of KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, primarily develops monoclonal antibody therapeutics for the treatment of respiratory diseases and cancer in the United States. Its product candidates include KB001-A, which is in a Phase II clinical trial for the prevention and treatment of pseudomonas aeruginosa infection in mechanically ventilated and cystic fibrosis patients; KB003 that is in a Phase II clinical trial for the treatment of inflammatory diseases; and KB004, which is in a Phase I clinical trial for the treatment of hematologic malignancies and solid tumors. The company has a collaboration agreement with Sanofi Pasteur S.A. for the development of KB001-A. KaloBios P...
260 East Grand Avenue
South San Francisco, CA 94080
Founded in 2000
Key Executives for KaloBios Pharmaceuticals, Inc.
Chief Executive Officer
Total Annual Compensation: $417.5K
Chief Medical Officer
Total Annual Compensation: $410.0K
Chief Scientific Officer and Executive Vice President of Research & Development
Total Annual Compensation: $287.5K
Compensation as of Fiscal Year 2013.
KaloBios Pharmaceuticals, Inc. Key Developments
KaloBios Pharmaceuticals, Inc. Reports Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014
Nov 6 14
KaloBios Pharmaceuticals, Inc. reported consolidated unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, contract revenue was $0 compared to $9,000 a year ago, the decrease in contract Revenue was due to the completion of all substantive performance obligations related to research support activities under collaboration agreement with Sanofi Pasteur. Loss from operations was $7,709,000 compared to $11,087,000 a year ago. Net loss was $8,063,000 or $0.24 basic and diluted per share compared to $11,329,000 or $0.47 basic and diluted per share a year ago. Research and development (R&D) expenses were $5.1 million as compared to $9.0 million for the same period in 2013.
For the nine months, contract revenue was $0 compared to $40,000 a year ago. Loss from operations was $27,403,000 compared to $30,981,000 a year ago. Net loss was $28,285,000 or $0.86 basic and diluted per share compared to $31,712,000 or $1.48 basic and diluted per share a year ago.
KaloBios Pharmaceuticals, Inc. Announces Board Changes, Effective October 10, 2014
Oct 8 14
On October 6, 2014, KaloBios Pharmaceuticals, Inc. announced that V. Bryan Lawlis, Ph.D., informed to the board of directors of the company that he is resigning as a member of the company's Board of Directors, effective as of October 10, 2014. Dr. Lawlis's resignation was not due to any dispute or disagreement with the Company over any matters, policy or otherwise. Instead, he informed the company that he has chosen to resign in light of the focus and nature of activities of the other companies where he currently serves on the board of directors. In connection with Dr. Lawlis's resignation, the Board of Directors on October 7, 2014 elected Ted W. Love, MD, to serve as a member of the Company's audit committee, effective as of Dr. Lawlis's resignation.
KaloBios Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Update on its Current Clinical Programs
Aug 7 14
KaloBios Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the second quarter, the company reported loss from operations was $9,534,000 compared with $11,586,000 for the same period in the last year. Net loss was $9,814,000 compared with $11,809,000 for the same period in the last year. Basic and diluted net loss per common share was $0.30 compared with $0.49 for the same period in the last year.
For the six months, the company reported loss from operations was $19,694,000 compared with $19,925,000 for the same period in the last year. Net loss was $20,222,000 compared with $20,383,000 for the same period in the last year. Basic and diluted net loss per common share was $0.61 compared with $1.02 for the same period in the last year.
The company provided an update on its current clinical programs. The company completed enrollment in July in the open-label Phase 1 dose escalation study of KB004 in hematologic malignancies. This study has enrolled a total of 50 patients in the Phase 1 portion of the study, including patients with myelodysplastic syndrome (MDS), myelofibrosis (MF) and acute myeloid leukemia (AML), with 80% of patients enrolled being late-stage AML patients. The drug continues to be well tolerated with the most commonly reported side effects being first-dose infusion reactions. No maximum tolerated dose (MTD) was reached in this study. Based on the outcome of the Phase 1 portion of the study, KaloBios has declared 250mg as the high dose for purposes of the Phase 2 expansion portion of the study. The Phase 2 expansion portion of the study will be enrolling patients with hematologic malignancies that are pre-screened to be EphA3 positive. Now that the high-dose has been declared, KaloBios will seek to enroll one high-dose cohort of 10 MDS patients, a second high-dose cohort of 10 AML patients, and a third high-dose cohort comprised of 10 MF patients. In July, KaloBios announced that target enrollment in the Phase 2 study in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (Pa) lung infections was achieved with the enrollment of the 180(th) patient. KaloBios expects to release top-line data on this study early in the first quarter of 2015. It also at that time announced that it had regained full global rights to KB001-A in all indications as a result of the execution of a negotiated termination of the company's collaboration agreement with Sanofi Pasteur. KaloBios has stated that it intends to seek a partner with a focus on infectious disease, hospital pharmaceuticals, or cystic fibrosis who can accelerate and financially support the future development of KB001-A.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|